Please use this identifier to cite or link to this item:
Title: Effect of Penetration Enhancers and Safety on the Transdermal Delivery of Apremilast in Skin
Author: Sarango Granda, Paulo
Espinoza, Lupe Carolina
Díaz Garrido, Natalia
Alvarado Bonilla, Helen Lissette
Rodríguez Lagunas, María José
Baldomà Llavinés, Laura
Calpena Campmany, Ana Cristina
Keywords: Malalties de la pell
Sistemes d'alliberament de medicaments
Skin diseases
Drug delivery systems
Issue Date: 7-May-2022
Publisher: MDPI
Abstract: The poor water solubility of apremilast (APR) is the main impediment to the penetration of the drug through the skin barrier. The objective of this study was to evaluate the permeability of APR in different solutions enriched with penetration promoters in ex vivo samples of human skin, and additionally assess its tolerance in vivo. To this end, APR solutions with 5% promoter were developed, and the drug's ability to penetrate human abdominal skin samples was evaluated; the coefficients of permeability, cumulated amounts permeated, and flow were some of the parameters evaluated; likewise, the in vitro and in vivo tolerance of the solutions was evaluated. The results obtained showed that the solutions containing squalene as a promoter improved the penetration of APR compared to the other promoters evaluated; in the same way, on an in vitro scale in HaCaT cells, the promoters were not toxic, finding a cell viability greater than 80% at the different dilutions evaluated. In the in vivo tests carried out with the solution that presented the best results (APRSqualene solution), it was observed that it does not cause irritation or erythema on the skin after its colorimetric and histological evaluation of the dorsal region of rats after its application. Squalene becomes an excellent candidate to improve the permeability of the drug in the case of the development of a topical formulation; in addition, it was confirmed that this penetration enhancer is neither toxic nor irritating when in contact with the skin in in vivo tests.
Note: Reproducció del document publicat a:
It is part of: Pharmaceutics, 2022, vol. 14, p. 1011
Related resource:
ISSN: 1999-4923
Appears in Collections:Articles publicats en revistes (Bioquímica i Fisiologia)

Files in This Item:
File Description SizeFormat 
723352.pdf2.73 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons